HRP20180444T1 - 9-aminometil-supstituirani tetraciklinski spojevi - Google Patents
9-aminometil-supstituirani tetraciklinski spojevi Download PDFInfo
- Publication number
- HRP20180444T1 HRP20180444T1 HRP20180444TT HRP20180444T HRP20180444T1 HR P20180444 T1 HRP20180444 T1 HR P20180444T1 HR P20180444T T HRP20180444T T HR P20180444TT HR P20180444 T HRP20180444 T HR P20180444T HR P20180444 T1 HRP20180444 T1 HR P20180444T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound according
- Prior art date
Links
- 239000004098 Tetracycline Substances 0.000 title 1
- 229960002180 tetracycline Drugs 0.000 title 1
- 229930101283 tetracycline Natural products 0.000 title 1
- 235000019364 tetracycline Nutrition 0.000 title 1
- -1 tetracycline compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/40—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
- C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
- C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
- C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Claims (7)
1. Spoj opće formule I:
[image]
,
ili njegova farmaceutski prihvatljiva sol ili solvat,
naznačen time što
svaki od R2a, R2b, R3, R10, R11 i R12 je neovisno vodik;
svaki od R5, R6a, R6b i R8 je neovisno vodik;
R7 je NR7aR7b;
svaki od R4a, R4b, R7a i R7b je neovisno vodik ili C1-6alkil;
svaki od R9a i R9b je neovisno
(1) bilo koji od njih je vodik, a drugi je:
(a) ciklobutilna ili 6- do 12-eročlana spirociklička skupina, gdje gore navedene skupine nisu supstituirane ili su supstituirane s 1 do 3 supstituenta, koji mogu biti isti ili različiti i bira ih se između Q1; ili
(b) ciklobutilC1-6alkilna ili 6- do 12-eročlana spirociklička skupina C1-6alkil, gdje gore navedene skupine nisu supstituirane ili su supstituirane s 1 do 3 supstituenta, koji mogu biti isti ili različiti i bira ih se između Q1, a jedan ili više ugljika u navedenom ciklobutilu mogu biti zamijenjeni jednim atomom kisika;
alternativno,
(2) R9a i R9b, zajedno s atomom dušika na kojeg su vezani, tvore azetidinil, 6- do 9-eročlanu spirocikličku skupinu ili 6- do 9-eročlanu zasićenu kondenziranu prstenastu skupinu, gdje gore navedene skupine nisu supstituirane ili su supstituirane s 1 do 3 supstituenta Q2, koji mogu biti isti ili različiti, a jedan ili više ugljika u navedenoj 6- do 9-eročlanoj spirocikličkoj skupini mogu biti zamijenjeni jednim atomom kisika;
Q1 i Q2 se neovisno bira između halogena, amino ili C1-6alkila;
svaki od R13a i R13b je neovisno vodik.
2. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili solvat, naznačen time što formula (I) ima strukturu prikazanu formulom (II), kao niže:
[image]
,
gdje je svaki od R9a i R9b neovisno definiran kao u patentnom zahtjevu 1.
3. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili solvat, naznačen time što formula (I) ima strukturu prikazanu formulom (III), kao niže:
[image]
,
gdje je svaki od R9a i R9b neovisno definiran kao u patentnom zahtjevu 1.
4. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili solvat, naznačen time što se spoj bira između:
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
i
[image]
.
5. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol ili solvat, kao i farmaceutski prihvatljivu podlogu i/ili razrjeđivač.
6. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili solvat, naznačen time što je namijenjen upotrebi u liječenju i/ili profilaksi infekcija, raka i dijabetesa.
7. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili solvat, naznačen time što je spoj
[image]
.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110222016 | 2011-07-26 | ||
| EP12817774.8A EP2738156B1 (en) | 2011-07-26 | 2012-07-26 | 9-aminomethyl substituted tetracycline compounds |
| PCT/CN2012/001001 WO2013013505A1 (zh) | 2011-07-26 | 2012-07-26 | 9-氨基甲基取代的四环素类化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180444T1 true HRP20180444T1 (hr) | 2018-05-04 |
Family
ID=47600513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180444TT HRP20180444T1 (hr) | 2011-07-26 | 2018-03-15 | 9-aminometil-supstituirani tetraciklinski spojevi |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9365499B2 (hr) |
| EP (1) | EP2738156B1 (hr) |
| JP (1) | JP5792902B2 (hr) |
| KR (1) | KR101732084B1 (hr) |
| CN (1) | CN103717571B8 (hr) |
| BR (1) | BR112014001798B1 (hr) |
| CA (1) | CA2842838C (hr) |
| DK (1) | DK2738156T3 (hr) |
| ES (1) | ES2664516T3 (hr) |
| HK (1) | HK1191931A1 (hr) |
| HR (1) | HRP20180444T1 (hr) |
| HU (1) | HUE036696T2 (hr) |
| LT (1) | LT2738156T (hr) |
| NO (1) | NO2738156T3 (hr) |
| PL (1) | PL2738156T3 (hr) |
| PT (1) | PT2738156T (hr) |
| SI (1) | SI2738156T1 (hr) |
| WO (1) | WO2013013505A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| AR084824A1 (es) | 2011-01-10 | 2013-06-26 | Intellikine Inc | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| HUE036696T2 (hu) | 2011-07-26 | 2018-07-30 | Kbp Biosciences Usa Inc | 9-aminometil-szubsztituált tetraciklin-vegyületek |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CN103073481A (zh) * | 2013-02-06 | 2013-05-01 | 上海药明康德新药开发有限公司 | 一种4-氮杂螺[2.4]庚烷盐酸盐的制备方法 |
| US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN105384673B (zh) * | 2015-11-09 | 2017-11-14 | 南京富润凯德生物医药有限公司 | 3‑氟代‑氮杂环丁烷衍生物的合成方法 |
| AU2017282891B2 (en) | 2016-06-22 | 2020-01-02 | Kbp Biosciences Co., Ltd. | Crystal form of 9-aminomethyl substituted tetracycline compounds and preparation method therefor |
| SG11201811237WA (en) | 2016-06-24 | 2019-01-30 | Infinity Pharmaceuticals Inc | Combination therapies |
| CN106883138B (zh) * | 2017-03-01 | 2018-07-10 | 郑州大学第一附属医院 | 老虎素的制备方法 |
| JP7418345B2 (ja) * | 2018-04-06 | 2024-01-19 | パラテック ファーマシューティカルズ，インコーポレイテッド | サレサイクリン塩酸塩を製造する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE544745T1 (de) | 2000-07-07 | 2012-02-15 | Tufts College | 9-substituierte minocyclinverbindungen |
| AU2002354619A1 (en) * | 2001-07-13 | 2003-01-29 | Centillium Communications, Inc. | Application of metering tones to a dsl and voice communications system |
| EA201000491A1 (ru) | 2002-03-08 | 2010-08-30 | Паратек Фармасьютикалс, Инк. | Аминометилзамещенные тетрациклиновые соединения |
| AU2003287218C1 (en) | 2002-10-24 | 2010-07-15 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| WO2004064728A2 (en) * | 2003-01-16 | 2004-08-05 | Paratek Pharmaceuticals, Inc. | Use of specific tetracycline compounds in therapy |
| EP2298323A3 (en) * | 2003-07-09 | 2011-05-11 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| CA2673466C (en) | 2006-12-21 | 2016-06-14 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| CN101759604A (zh) * | 2008-09-12 | 2010-06-30 | 山东轩竹医药科技有限公司 | 胍基取代的四环素衍生物 |
| HUE036696T2 (hu) | 2011-07-26 | 2018-07-30 | Kbp Biosciences Usa Inc | 9-aminometil-szubsztituált tetraciklin-vegyületek |
-
2012
- 2012-07-26 HU HUE12817774A patent/HUE036696T2/hu unknown
- 2012-07-26 KR KR1020147005035A patent/KR101732084B1/ko active IP Right Grant
- 2012-07-26 DK DK12817774.8T patent/DK2738156T3/en active
- 2012-07-26 LT LTEP12817774.8T patent/LT2738156T/lt unknown
- 2012-07-26 BR BR112014001798-0A patent/BR112014001798B1/pt active IP Right Grant
- 2012-07-26 WO PCT/CN2012/001001 patent/WO2013013505A1/zh active Application Filing
- 2012-07-26 ES ES12817774.8T patent/ES2664516T3/es active Active
- 2012-07-26 CA CA2842838A patent/CA2842838C/en active Active
- 2012-07-26 SI SI201231256T patent/SI2738156T1/en unknown
- 2012-07-26 US US14/234,420 patent/US9365499B2/en active Active
- 2012-07-26 NO NO12817774A patent/NO2738156T3/no unknown
- 2012-07-26 CN CN201280037036.6A patent/CN103717571B8/zh active Active
- 2012-07-26 EP EP12817774.8A patent/EP2738156B1/en active Active
- 2012-07-26 PT PT128177748T patent/PT2738156T/pt unknown
- 2012-07-26 JP JP2014521914A patent/JP5792902B2/ja active Active
- 2012-07-26 PL PL12817774T patent/PL2738156T3/pl unknown
-
2014
- 2014-06-06 HK HK14105301.7A patent/HK1191931A1/zh unknown
-
2018
- 2018-03-15 HR HRP20180444TT patent/HRP20180444T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2738156T3 (en) | 2018-03-26 |
| EP2738156B1 (en) | 2018-01-03 |
| PT2738156T (pt) | 2018-03-28 |
| CA2842838A1 (en) | 2013-01-31 |
| KR20140050694A (ko) | 2014-04-29 |
| LT2738156T (lt) | 2018-05-25 |
| CN103717571B8 (zh) | 2017-05-17 |
| PL2738156T3 (pl) | 2018-06-29 |
| ES2664516T3 (es) | 2018-04-19 |
| CN103717571A (zh) | 2014-04-09 |
| JP2014529342A (ja) | 2014-11-06 |
| US9365499B2 (en) | 2016-06-14 |
| EP2738156A1 (en) | 2014-06-04 |
| KR101732084B1 (ko) | 2017-05-02 |
| NO2738156T3 (hr) | 2018-06-02 |
| HUE036696T2 (hu) | 2018-07-30 |
| CN103717571B (zh) | 2016-01-13 |
| BR112014001798A2 (pt) | 2017-02-21 |
| US20140179638A1 (en) | 2014-06-26 |
| HK1191931A1 (zh) | 2014-08-08 |
| BR112014001798B1 (pt) | 2021-07-27 |
| WO2013013505A1 (zh) | 2013-01-31 |
| JP5792902B2 (ja) | 2015-10-14 |
| CA2842838C (en) | 2017-04-25 |
| SI2738156T1 (en) | 2018-05-31 |
| EP2738156A4 (en) | 2015-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180444T1 (hr) | 9-aminometil-supstituirani tetraciklinski spojevi | |
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| JOP20190070A1 (ar) | مركبات بنزو[b] ثيوفين كناهضات محفزة لبروتين جينات الإنترفيرون | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| HRP20180791T1 (hr) | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20170654T1 (hr) | Makrociklički deaza-purinoni za liječenje virusnih infekcija | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| EA030189B8 (ru) | Аналоги 2'-хлоронуклеозидов для инфекции вгс | |
| UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
| BR112014000563A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| MD20140084A2 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| AR081830A1 (es) | Activadores de guanilato ciclasa soluble, composiciones farmaceuticas que los comprenden y sus usos | |
| NI201400023A (es) | Derivados de pirrolopirimidina y purina | |
| WO2014209841A3 (en) | Compounds for treating spinal muscular atrophy | |
| RU2015109132A (ru) | Пролекарственная форма тенофовира и ее фармацевтические применения | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR080987A1 (es) | Formas cristalinas polimorficas a y d de la sal mesilato de 7-metil-5(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluorometoxibencil)2,3-dihidroisoindol-1-ona,metodo para prepararlas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del dolor y la ansied | |
| JP2019510034A5 (hr) | ||
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| WO2015021396A3 (en) | Tricyclic benzoxaborole compounds and uses thereof | |
| JP2016540803A5 (hr) | ||
| JP2015516427A5 (hr) | ||
| MA34055B1 (fr) | Chlorhydrate d'agomelatine hydrate et sa preparation | |
| JP2017525699A5 (hr) | ||
| MX2018006225A (es) | Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash). |